|
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
|
Oct 2019
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency
|
Oct 2019
|
The Journal of Clinical Investigation
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes
|
Oct 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
The evolving role of next generation sequencing in myelodysplastic syndromes
|
Oct 2019
|
British Journal of Haematology
|
myelodysplastic syndromes (MDS)
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
|
Sep 2019
|
JCO Precision Oncology
|
myelodysplastic syndromes (MDS)
|
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
|
Sep 2019
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
